Novel Therapies in Acute Lymphoblastic Leukemia

2007 ◽  
pp. 237-246
Author(s):  
Stefan H. Faderl ◽  
Hagop Kantarjian
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Novel Therapies

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

2018 ◽  
Vol 13 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Nicholas J. Short ◽  
Hagop Kantarjian ◽  
Elias Jabbour ◽  
Farhad Ravandi
Keyword(s):  
Older Adults ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Novel Therapies

scholarly journals Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Blood ◽  
2016 ◽  
Vol 127 (15) ◽  
pp. 1863-1869 ◽  
Author(s):  
Nitin Jain ◽  
Audrey V. Lamb ◽  
Susan O’Brien ◽  
Farhad Ravandi ◽  
Marina Konopleva ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
High Risk ◽  
Lymphoblastic Leukemia ◽  
Adult Patients ◽  
Novel Therapies ◽  
Long Term Outcomes ◽  
Cell Precursor ◽  
Key Points ◽  
Adolescents And Adults

Key Points Adult patients with ETP-ALL/LBL have poor long-term outcomes. Novel therapies are urgently needed for adult patients with ETP-ALL/LBL.

scholarly journals Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies

2021 ◽  
Vol 11 ◽  
Author(s):  
Chun-fung Sin ◽  
Pui-hei Marcus Man
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Molecular Pathogenesis ◽  
Current Understanding ◽  
Cell Transplant ◽  
Novel Therapies ◽  
Cell Precursor ◽  
Allogenic Stem Cell Transplant ◽  
Induction Failure

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a distinct subtype of T lymphoblastic leukemia (T-ALL) identified in 2009, due to its unique immunophenotypic and genomic profile. The outcome of patients was poor in earlier studies, and they were prone to have induction failure, with more frequent relapse/refractory disease. Recent advances had been made in discoveries of genetic aberrations and molecular pathogenesis of ETP-ALL. However, the diagnosis and management of ETP-ALL is still challenging. There are limited choices of novel therapies so far. In this review article, it highlighted the diagnostic issue of ETP-ALL, pitfall in diagnosis, and strategy of accurate diagnosis. The review also summarized current understanding of molecular mechanism of leukemogenesis. The emerging role of risk-adapted therapy and allogenic stem cell transplant in optimizing the outcome of patients with ETP-ALL was discussed. Finally, some potential novel therapies were proposed based on the current understanding of molecular pathogenesis.

scholarly journals Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL

Blood ◽  
2019 ◽  
Vol 133 (16) ◽  
pp. 1715-1719 ◽  
Author(s):  
Emily Curran ◽  
Wendy Stock
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Important Predictor ◽  
Novel Therapies ◽  
Current Therapies ◽  
Minimal Residual ◽  
Bispecific T Cell Engager

Abstract Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.

scholarly journals Novel therapies for relapsed acute lymphoblastic leukemia

2009 ◽  
Vol 4 (3) ◽  
pp. 148-156 ◽  
Author(s):  
Amber Fullmer ◽  
Susan O’Brien ◽  
Hagop Kantarjian ◽  
Elias Jabbour
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Novel Therapies
Sign in / Sign up

Export Citation Format

Share Document